Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 348

1.

Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease.

Torres VE, King BF, Chapman AB, Brummer ME, Bae KT, Glockner JF, Arya K, Risk D, Felmlee JP, Grantham JJ, Guay-Woodford LM, Bennett WM, Klahr S, Meyers CM, Zhang X, Thompson PA, Miller JP; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP).

Clin J Am Soc Nephrol. 2007 Jan;2(1):112-20. Epub 2006 Nov 2.

2.

Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort.

Bae KT, Zhu F, Chapman AB, Torres VE, Grantham JJ, Guay-Woodford LM, Baumgarten DA, King BF Jr, Wetzel LH, Kenney PJ, Brummer ME, Bennett WM, Klahr S, Meyers CM, Zhang X, Thompson PA, Miller JP; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP).

Clin J Am Soc Nephrol. 2006 Jan;1(1):64-9. Epub 2005 Oct 26.

3.

Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease.

Harris PC, Bae KT, Rossetti S, Torres VE, Grantham JJ, Chapman AB, Guay-Woodford LM, King BF, Wetzel LH, Baumgarten DA, Kenney PJ, Consugar M, Klahr S, Bennett WM, Meyers CM, Zhang QJ, Thompson PA, Zhu F, Miller JP.

J Am Soc Nephrol. 2006 Nov;17(11):3013-9. Epub 2006 Oct 11.

4.

One physician's exploration of the ethics in the practice of medicine.

Klahr S.

Kidney Int. 2006 Aug;70(4):613-4. No abstract available.

5.

Volume progression in polycystic kidney disease.

Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF Jr, Wetzel LH, Baumgarten DA, Kenney PJ, Harris PC, Klahr S, Bennett WM, Hirschman GN, Meyers CM, Zhang X, Zhu F, Miller JP; CRISP Investigators.

N Engl J Med. 2006 May 18;354(20):2122-30.

6.

Nephrology at Washington University School of Medicine: my early days.

Klahr S.

Kidney Int. 2006 May;69(9):1487-8. No abstract available.

7.

Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the consortium of radiologic imaging studies of polycystic kidney disease cohort.

Rule AD, Torres VE, Chapman AB, Grantham JJ, Guay-Woodford LM, Bae KT, Klahr S, Bennett WM, Meyers CM, Thompson PA, Miller JP; CRISP Consortium.

J Am Soc Nephrol. 2006 Mar;17(3):854-62. Epub 2006 Feb 1.

8.

The early days of nephrology in Colombia.

Klahr S.

Kidney Int. 2006 Jan;69(2):199-200. No abstract available.

9.

A uniform clinical trial registration policy for journals of kidney diseases, dialysis, and transplantation.

Couser W, Drueke T, Halloran P, Kasiske B, Klahr S, Morris P.

Transplantation. 2005 Apr 15;79(7):751. No abstract available. Erratum in: Transplantation. 2005 May 27;79(10):1463.

PMID:
15818314
10.

Trial registry policy: common editorial statement a uniform clinical trial registration policy for journals of kidney diseases, dialysis and transplantation.

Couser W, Dr├╝eke T, Halloran P, Kasiske B, Klahr S, Morris P.

Nephrol Dial Transplant. 2005 Apr;20(4):691. No abstract available. Erratum in: Nephrol Dial Transplant. 2005 Jun;20(6):1282.

PMID:
15772264
11.

A uniform clinical trial registration policy for journals of kidney diseases, dialysis and transplantation.

Couser WG, Drueke TB, Halloran PF, Kasiske BL, Klahr S, Morris P.

Am J Transplant. 2005 Apr;5(4 Pt 1):643. No abstract available.

12.

Uniform clinical trial registration policy for journals of kidney diseases, dialysis, and transplantation.

Couser WG, Drueke T, Halloran P, Kasiske B, Klahr S, Morris P.

J Am Soc Nephrol. 2005 Apr;16(4):837. Epub 2005 Mar 2. No abstract available. Erratum in: J Am Soc Nephrol. 2005 Jun;16(6):1867.

13.

L-arginine as a therapeutic tool in kidney disease.

Klahr S, Morrissey J.

Semin Nephrol. 2004 Jul;24(4):389-94. Review.

PMID:
15252778
14.

Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease.

King BF, Torres VE, Brummer ME, Chapman AB, Bae KT, Glockner JF, Arya K, Felmlee JP, Grantham JJ, Guay-Woodford LM, Bennett WM, Klahr S, Hirschman GH, Kimmel PL, Thompson PA, Miller JP; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP).

Kidney Int. 2003 Dec;64(6):2214-21.

15.
16.

Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort.

Chapman AB, Guay-Woodford LM, Grantham JJ, Torres VE, Bae KT, Baumgarten DA, Kenney PJ, King BF Jr, Glockner JF, Wetzel LH, Brummer ME, O'Neill WC, Robbin ML, Bennett WM, Klahr S, Hirschman GH, Kimmel PL, Thompson PA, Miller JP; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort.

Kidney Int. 2003 Sep;64(3):1035-45.

17.
18.

Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy.

Wang S, Chen Q, Simon TC, Strebeck F, Chaudhary L, Morrissey J, Liapis H, Klahr S, Hruska KA.

Kidney Int. 2003 Jun;63(6):2037-49.

19.

High urine volume and low urine osmolality are risk factors for faster progression of renal disease.

Hebert LA, Greene T, Levey A, Falkenhain ME, Klahr S.

Am J Kidney Dis. 2003 May;41(5):962-71.

PMID:
12722030
20.

Progression of chronic renal disease.

Klahr S, Morrissey J.

Am J Kidney Dis. 2003 Mar;41(3 Suppl 1):S3-7. Review.

PMID:
12612942
21.

ACE inhibition increases expression of the ETB receptor in kidneys of mice with unilateral obstruction.

Moridaira K, Morrissey J, Fitzgerald M, Guo G, McCracken R, Tolley T, Klahr S.

Am J Physiol Renal Physiol. 2003 Jan;284(1):F209-17.

22.
23.

Obstructive nephropathy and renal fibrosis.

Klahr S, Morrissey J.

Am J Physiol Renal Physiol. 2002 Nov;283(5):F861-75. Review.

24.

Renal physiology between two wars: the contributions of Dr. Harvey Lester White.

Purkerson ML, Klahr S.

Am J Nephrol. 2002 Jul;22(2-3):180-5.

PMID:
12097737
25.

Transforming growth factor-beta induces renal epithelial jagged-1 expression in fibrotic disease.

Morrissey J, Guo G, Moridaira K, Fitzgerald M, McCracken R, Tolley T, Klahr S.

J Am Soc Nephrol. 2002 Jun;13(6):1499-508.

26.

New approaches to delay the progression of chronic renal failure.

Klahr S, Morrissey J, Hruska K, Wang S, Chen Q.

Kidney Int Suppl. 2002 May;(80):23-6. Review.

PMID:
11982808
27.

Progression of chronic renal disease.

Klahr S.

Heart Dis. 2001 May-Jun;3(3):205-9. Review.

PMID:
11975793
28.

Bone morphogenetic protein-7 improves renal fibrosis and accelerates the return of renal function.

Morrissey J, Hruska K, Guo G, Wang S, Chen Q, Klahr S.

J Am Soc Nephrol. 2002 Jan;13 Suppl 1:S14-21.

29.

The role of nitric oxide in hypertension and renal disease progression.

Klahr S.

Nephrol Dial Transplant. 2001;16 Suppl 1:60-2. Review.

PMID:
11369823
30.

Contributions of angiotensin II and tumor necrosis factor-alpha to the development of renal fibrosis.

Guo G, Morrissey J, McCracken R, Tolley T, Liapis H, Klahr S.

Am J Physiol Renal Physiol. 2001 May;280(5):F777-85.

31.

Urinary tract obstruction.

Klahr S.

Semin Nephrol. 2001 Mar;21(2):133-45. Review.

PMID:
11245776
32.

A look back and a look toward the future

Klahr S.

Kidney Int. 2001 Jan;59(1):1-2. No abstract available.

33.

Induction of CD14 in tubular epithelial cells during kidney disease.

Morrissey J, Guo G, McCracken R, Tolley T, Klahr S.

J Am Soc Nephrol. 2000 Sep;11(9):1681-90.

34.

Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction.

Hruska KA, Guo G, Wozniak M, Martin D, Miller S, Liapis H, Loveday K, Klahr S, Sampath TK, Morrissey J.

Am J Physiol Renal Physiol. 2000 Jul;279(1):F130-43.

35.

Obstructive nephropathy.

Klahr S.

Intern Med. 2000 May;39(5):355-61. Review.

36.

The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease.

Klahr S, Morrissey JJ.

Kidney Int Suppl. 2000 Apr;75:S7-14. Review.

PMID:
10828755
37.

Mechanisms of progression of chronic renal damage.

Klahr S.

J Nephrol. 1999 Jul-Aug;12 Suppl 2:S53-62. Review.

PMID:
10688403
38.

Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? Modification of Diet in Renal Disease Study group.

Levey AS, Greene T, Beck GJ, Caggiula AW, Kusek JW, Hunsicker LG, Klahr S.

J Am Soc Nephrol. 1999 Nov;10(11):2426-39. Review.

39.

Report from the Editor.

Klahr S.

Kidney Int. 1999 Nov;56(5):2000. No abstract available.

40.

Role of TNFR1 and TNFR2 receptors in tubulointerstitial fibrosis of obstructive nephropathy.

Guo G, Morrissey J, McCracken R, Tolley T, Klahr S.

Am J Physiol. 1999 Nov;277(5):F766-72. doi: 10.1152/ajprenal.1999.277.5.F766.

PMID:
10564241
41.

The geriatric patient with obstructive uropathy.

Klahr S.

Geriatr Nephrol Urol. 1999;9(2):101-7. Review. No abstract available.

PMID:
10518253
42.

Can L-arginine manipulation reduce renal disease?

Klahr S.

Semin Nephrol. 1999 May;19(3):304-9. Review.

PMID:
10226337
43.

Effect of AT2 receptor blockade on the pathogenesis of renal fibrosis.

Morrissey JJ, Klahr S.

Am J Physiol. 1999 Jan;276(1):F39-45. doi: 10.1152/ajprenal.1999.276.1.F39.

PMID:
9887078
44.

Effect of a ketoacid-aminoacid-supplemented very low protein diet on the progression of advanced renal disease: a reanalysis of the MDRD feasibility study.

Teschan PE, Beck GJ, Dwyer JT, Greene T, Klahr S, Levy AS, Mitch WE, Snetselaar LG, Steinman TI, Walser M.

Clin Nephrol. 1998 Nov;50(5):273-83.

PMID:
9840314
45.

Therapeutic approaches in obstructive uropathy.

Chevalier RL, Klahr S.

Semin Nephrol. 1998 Nov;18(6):652-8. Review.

PMID:
9819156
46.

The role of growth factors, cytokines, and vasoactive compounds in obstructive nephropathy.

Klahr S, Morrissey JJ.

Semin Nephrol. 1998 Nov;18(6):622-32. Review.

PMID:
9819153
47.

Transcription factor NF-kappaB regulation of renal fibrosis during ureteral obstruction.

Morrissey J, Klahr S.

Semin Nephrol. 1998 Nov;18(6):603-11. Review.

PMID:
9819151
48.

Mechanisms of interstitial fibrosis in obstructive nephropathy.

Diamond JR, Ricardo SD, Klahr S.

Semin Nephrol. 1998 Nov;18(6):594-602. Review.

PMID:
9819150
49.

The role of L-arginine in hypertension and nephrotoxicity.

Klahr S.

Curr Opin Nephrol Hypertens. 1998 Sep;7(5):547-50. Review.

PMID:
9818202
50.

Obstructive nephropathy.

Klahr S.

Kidney Int. 1998 Jul;54(1):286-300. No abstract available.

PMID:
9648093

Supplemental Content

Support Center